Literature DB >> 22476306

Does a study focused on trauma encourage patients with psychotic symptoms to seek treatment?

Lawrence V Amsel1, Noel Hunter, San Kim, Kinga E Fodor, John C Markowitz.   

Abstract

OBJECTIVE: This study explored, in a randomized trial of psychotherapies for posttraumatic stress disorder (PTSD), why a surprisingly high percentage of study applicants presented with psychotic symptoms and what clinical implications this finding might prompt.
METHODS: Raters reviewed the records of applicants who completed an initial psychiatric interview and compared those who had psychotic symptoms with all other study-eligible participants and with those who ultimately were enrolled in the study.
RESULTS: Of 223 consecutively evaluated individuals who applied for study entry, 38 (17%) were found ineligible because of psychotic symptoms. These individuals were more likely to be male and to have suffered child abuse, and they had taken a greater number of lifetime medications than study-eligible applicants. Most individuals with psychotic symptoms met DSM-IV criteria for PTSD.
CONCLUSIONS: A trauma-informed framework might be a helpful part of a comprehensive treatment plan for some individuals with psychotic symptoms, possibly leading to greater treatment engagement and more positive outcomes.

Entities:  

Mesh:

Year:  2012        PMID: 22476306      PMCID: PMC3617213          DOI: 10.1176/appi.ps.201100251

Source DB:  PubMed          Journal:  Psychiatr Serv        ISSN: 1075-2730            Impact factor:   3.084


  7 in total

1.  Reliability of reports of violent victimization and posttraumatic stress disorder among men and women with serious mental illness.

Authors:  L A Goodman; K M Thompson; K Weinfurt; S Corl; P Acker; K T Mueser; S D Rosenberg
Journal:  J Trauma Stress       Date:  1999-10

Review 2.  Cognitive behavioral therapy for schizophrenia.

Authors:  Shanaya Rathod; Peter Phiri; David Kingdon
Journal:  Psychiatr Clin North Am       Date:  2010-09

Review 3.  The development of a Clinician-Administered PTSD Scale.

Authors:  D D Blake; F W Weathers; L M Nagy; D G Kaloupek; F D Gusman; D S Charney; T M Keane
Journal:  J Trauma Stress       Date:  1995-01

Review 4.  Trauma exposure and posttraumatic stress disorder in adults with severe mental illness: a critical review.

Authors:  Anouk L Grubaugh; Heidi M Zinzow; Lisa Paul; Leonard E Egede; B Christopher Frueh
Journal:  Clin Psychol Rev       Date:  2011-04-27

Review 5.  Posttraumatic stress disorder with secondary psychotic features: neurobiological findings.

Authors:  Mario H Braakman; Frank A M Kortmann; Wim van den Brink; Robbert J Verkes
Journal:  Prog Brain Res       Date:  2008       Impact factor: 2.453

6.  Exposure-based cognitive-behavioral treatment of PTSD in adults with schizophrenia or schizoaffective disorder: a pilot study.

Authors:  B Christopher Frueh; Anouk L Grubaugh; Karen J Cusack; Matthew O Kimble; Jon D Elhai; Rebecca G Knapp
Journal:  J Anxiety Disord       Date:  2009-02-14

7.  The psychological consequences of combat exposure: the importance of appraisals and post-traumatic stress disorder symptomatology in the occurrence of delusional-like ideas.

Authors:  Michelle L C Campbell; Anthony P Morrison
Journal:  Br J Clin Psychol       Date:  2007-06
  7 in total
  2 in total

1.  Measuring trauma and stressful events in childhood and adolescence among patients with first-episode psychosis: initial factor structure, reliability, and validity of the Trauma Experiences Checklist.

Authors:  Sarah L Cristofaro; Sean D Cleary; Claire Ramsay Wan; Beth Broussard; Colby Chapman; Patrick J Haggard; Sara Jananeh; Neely L Myers; Michael T Compton
Journal:  Psychiatry Res       Date:  2013-07-11       Impact factor: 3.222

2.  Is Exposure Necessary? A Randomized Clinical Trial of Interpersonal Psychotherapy for PTSD.

Authors:  John C Markowitz; Eva Petkova; Yuval Neria; Page E Van Meter; Yihong Zhao; Elizabeth Hembree; Karina Lovell; Tatyana Biyanova; Randall D Marshall
Journal:  Am J Psychiatry       Date:  2015-02-13       Impact factor: 18.112

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.